Hideaki Ogiwara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hideaki Ogiwara has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Mariko Sasaki
Division of Cancer Therapeutics, National Cancer Center Research Institute, Tokyo, Japan
22 shared publications - Hiroshi Yoshida
Department of Diagnostic Pathology National Cancer Center Hospital Tokyo Japan
21 shared publications - Daiki Kato
Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan
20 shared publications - Takafumi Shimizu
Cancer Research Unit, Sumitomo Pharma Co., Ltd, Osaka, Japan
20 shared publications - Takashi Kohno
National Cancer Center Research Institute, Tokyo, Japan
14 shared publications Ayako Ui
Authors' Affiliations: 1Division of Dynamic Proteome in Cancer and Aging, Institute of Development, Aging and Cancer, Tohoku University, Sendai; 2Division of Genome Biology, National Cancer Center Research Institute, Tokyo; and 3Department of Biotechnology Research, Kazusa DNA Research Institute, Chiba, Japan
12 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Characterization of novel GCLC inhibitors as selective therapeutic agents for SMARCB1-deficient tumors (related to Figure 1)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Characterization of novel GCLC inhibitors as selective therapeutic agents for SMARCB1-deficient tumors (related to Figure 1)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
SMARCB1 contributes to SLC7A11 transcriptional activation and modulates the stress response (related to Figure 4)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
SMARCB1 contributes to SLC7A11 transcriptional activation and modulates the stress response (related to Figure 4)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
SMARCB1-deficient cells exhibit low basal GSH levels due to reduced SLC7A11 expression (related to Figure 3)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
SMARCB1-deficient cells exhibit low basal GSH levels due to reduced SLC7A11 expression (related to Figure 3)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Malignant rhabdoid tumors and epithelioid sarcomas, characterized by SMARCB1 deficiency, are aggressive cancers with limited effective treatments, necessitating development of therapeutic strategies. This study investigated the therapeutic efficacy and mechanism of action of inhibitors targeting glutamate–cysteine ligase catalytic subunit (GCLC) in these intractable malignancies. The GCLC inhibitors GCLCi0 (ONO-6428513) and GCLCi1 (ONO-7068506) demonstrated high selectivity and potent antitumor effects in SMARCB1-deficient cancer cells in mouse tumor xenograft models, surpassing the efficacy of existing drugs. GCLC inhibition led to the depletion of intracellular glutathione (GSH), an increase in reactive oxygen species, and elevated lipid peroxidation, ultimately inducing ferroptotic cell death. SMARCB1-deficient cells exhibited reduced expression of SLC7A11, which led to low basal GSH levels and sensitivity to GCLC inhibition. Significant synergistic effects were observed when GCLC inhibitors were combined with agents targeting the GSH synthesis pathway, specifically SLC7A11 inhibitors and the glutaminase inhibitor telaglenastat. In a mouse tumor xenograft model, the combination of a GCLC inhibitor and telaglenastat showed superior antitumor efficacy compared with monotherapy, with good tolerability. These findings highlight the vulnerability of GSH metabolism in SMARCB1-deficient cancers, suggesting that a GCLC inhibitor may be a promising therapeutic option. This study provides a preclinical foundation for the development of effective treatment strategies for SMARCB1-deficient cancers, including combination therapies, and supports further investigation toward future translational applications.Significance:GCLC inhibitors selectively induce ferroptosis in SMARCB1-deficient cancers by exploiting low glutathione levels and show potent synergy with glutaminase inhibitors.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Malignant rhabdoid tumors and epithelioid sarcomas, characterized by SMARCB1 deficiency, are aggressive cancers with limited effective treatments, necessitating development of therapeutic strategies. This study investigated the therapeutic efficacy and mechanism of action of inhibitors targeting glutamate–cysteine ligase catalytic subunit (GCLC) in these intractable malignancies. The GCLC inhibitors GCLCi0 (ONO-6428513) and GCLCi1 (ONO-7068506) demonstrated high selectivity and potent antitumor effects in SMARCB1-deficient cancer cells in mouse tumor xenograft models, surpassing the efficacy of existing drugs. GCLC inhibition led to the depletion of intracellular glutathione (GSH), an increase in reactive oxygen species, and elevated lipid peroxidation, ultimately inducing ferroptotic cell death. SMARCB1-deficient cells exhibited reduced expression of SLC7A11, which led to low basal GSH levels and sensitivity to GCLC inhibition. Significant synergistic effects were observed when GCLC inhibitors were combined with agents targeting the GSH synthesis pathway, specifically SLC7A11 inhibitors and the glutaminase inhibitor telaglenastat. In a mouse tumor xenograft model, the combination of a GCLC inhibitor and telaglenastat showed superior antitumor efficacy compared with monotherapy, with good tolerability. These findings highlight the vulnerability of GSH metabolism in SMARCB1-deficient cancers, suggesting that a GCLC inhibitor may be a promising therapeutic option. This study provides a preclinical foundation for the development of effective treatment strategies for SMARCB1-deficient cancers, including combination therapies, and supports further investigation toward future translational applications.Significance:GCLC inhibitors selectively induce ferroptosis in SMARCB1-deficient cancers by exploiting low glutathione levels and show potent synergy with glutaminase inhibitors.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Comparison of enzymatic and cellular activities of BSO, GCLCi0, and GCLCi1
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Comparison of enzymatic and cellular activities of BSO, GCLCi0, and GCLCi1
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Inhibition induces ferroptotic cell death by decreasing GSH and increasing lipid peroxidation (related to Figure 2)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Inhibition induces ferroptotic cell death by decreasing GSH and increasing lipid peroxidation (related to Figure 2)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
GCLC inhibitors synergize with GSH metabolism inhibitors in SMARCB1-deficient cells (related to Figure 5)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
GCLC inhibitors synergize with GSH metabolism inhibitors in SMARCB1-deficient cells (related to Figure 5)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Synergistic effects of GCLCi1 with Telaglenastat
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors
Synergistic effects of GCLCi1 with Telaglenastat
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from ARID1A Deficiency in Diffuse-Type Gastric Cancer Promotes a Pyrimidine Metabolic Vulnerability
Supplementary Figure S4 shows that Gemcitabine hypersensitivity is driven by competitive inhibition of impaired dC uptake and subsequent dCTP pool depletion.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from ARID1A Deficiency in Diffuse-Type Gastric Cancer Promotes a Pyrimidine Metabolic Vulnerability
Supplementary Figure S4 shows that Gemcitabine hypersensitivity is driven by competitive inhibition of impaired dC uptake and subsequent dCTP pool depletion.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from ARID1A Deficiency in Diffuse-Type Gastric Cancer Promotes a Pyrimidine Metabolic Vulnerability
Supplementary Table S1 shows a List of MRM transitions of metabolite isotopomers.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from ARID1A Deficiency in Diffuse-Type Gastric Cancer Promotes a Pyrimidine Metabolic Vulnerability
Supplementary Table S1 shows a List of MRM transitions of metabolite isotopomers.